LRMR — Larimar Therapeutics Share News
0.000.00%
Last trade - 00:00- $313.73m
- $157.46m
U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech
U.S. STOCKS ON THE MOVE-Electronic Arts, Copper miners, Occidental Petroleum
Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug
Brief: Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Larimar Therapeutics Q2 Net Income USD -26.182 Million
Larimar Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Altria, Meta, FuboTV
U.S. STOCKS ON THE MOVE-Electronic Arts, AEP, Peloton Interactive
U.S. STOCKS ON THE MOVE-Apple, Hershey, Wingstop
U.S. STOCKS ON THE MOVE-Visa, Kraft Heinz, Humana
Larimar Therapeutics falls after $60 mln equity raise
Brief: Larimar Therapeutics Prices Public Offering at $3.20 Per Share
Brief: Larimar Therapeutics Announces Proposed Underwritten Public Offering
Larimar Therapeutics falls on stock offering launch
Brief: Larimar Therapeutics Announces FDA Recommendations On Safety Database
Brief: Larimar Therapeutics announces regulatory update call on Nomlabofusp Program
Brief: Larimar Therapeutics Q1 Net Income USD -29.281 Million
Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary